| Hazard Information | Back Directory | [Uses]
Trabedersen (AP 12009) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2, such as those of the skin, pancreas and colon[1][2]. | [in vivo]
Trabedersen (initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week; i.p.) treatment significantly reduces tumor growth, lymph node metastasis and angiogenesis in an orthotopic mouse model of metastatic pancreatic cancer[2]. | Animal Model: | Eight-week-old male athymic nude mice (BALB?Cnu ?nu) bearing human pancreatic cancer cells[2]. | | Dosage: | Initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week. | | Administration: | Intraperitoneal (i.p.) injection; three times a week; for 27 days | | Result: | Significantly reduced tumor growth, lymph node metastasis and angiogenesis. |
| [References]
[1] Luc Vallières. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2. IDrugs. 2009 Jul;12(7):445-53. PMID:19579166
[2] Karl-Hermann Schlingensiepen, et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011 Jun;102(6):1193-200. DOI:10.1111/j.1349-7006.2011.01917.x |
|
|